General Information of Drug Combination (ID: DCB0Z9Q)

Drug Combination Name
Telmisartan Nifedipine
Indication
Disease Entry Status REF
Hypertension Phase 4 [1]
Component Drugs Telmisartan   DMS3GX2 Nifedipine   DMSVOZT
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Telmisartan
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Malignant essential hypertension BA00 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Stroke 8B20 Investigative [3]
Telmisartan Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Angiotensin II receptor type-1 (AGTR1) TT8DBY3 AGTR1_HUMAN Antagonist [7]
HUMAN type-1 angiotensin II receptor (AGTR1) TTPKMXQ AGTR1_HUMAN Blocker [8]
------------------------------------------------------------------------------------
Telmisartan Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [9]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Telmisartan Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [11]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Telmisartan Interacts with 8 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [13]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [14]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [15]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Expression [16]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Response To Substance [17]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Decreases Expression [18]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Decreases Expression [19]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Increases Activity [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DOT(s)
Indication(s) of Nifedipine
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [5]
Premature labour JB00 Approved [6]
Nifedipine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated L-type calcium channel (L-CaC) TTXHYV6 NOUNIPROTAC Modulator [21]
------------------------------------------------------------------------------------
Nifedipine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [22]
------------------------------------------------------------------------------------
Nifedipine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [23]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [24]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [25]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [26]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Metabolism [27]
------------------------------------------------------------------------------------
Nifedipine Interacts with 18 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [28]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [29]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [30]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [31]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [32]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Affects Expression [33]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [34]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Decreases Expression [35]
Fibroblast growth factor 7 (FGF7) OTGK6ANL FGF7_HUMAN Increases Expression [36]
Potassium voltage-gated channel subfamily A member 3 (KCNA3) OTXSP3AA KCNA3_HUMAN Decreases Activity [37]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Decreases Expression [38]
Myosin-11 (MYH11) OTVNVWY3 MYH11_HUMAN Increases Expression [38]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Increases Expression [35]
Oxidized low-density lipoprotein receptor 1 (OLR1) OTS44RIC OLR1_HUMAN Decreases Expression [39]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [40]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Decreases Expression [35]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [41]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Increases ADR [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 DOT(s)

References

1 ClinicalTrials.gov (NCT01830530) HIGH Altitude CArdiovascular REsearch in the ANDES
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 592).
3 Telmisartan FDA Label
4 ClinicalTrials.gov (NCT04359953) Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19. U.S. National Institutes of Health.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2514).
6 Nifedipine FDA Label
7 Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
8 Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
9 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
10 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
11 The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011 Sep;21(9):523-30.
12 Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35.
13 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
14 Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):241-9.
15 Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res. 2010 Aug;33(8):796-801. doi: 10.1038/hr.2010.107. Epub 2010 Jun 17.
16 Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res. 2005 Dec;28(12):987-94. doi: 10.1291/hypres.28.987.
17 Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension. 2008 Feb;51(2):259-66. doi: 10.1161/HYPERTENSIONAHA.107.099028. Epub 2007 Dec 24.
18 Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res. 2008 May;31(5):921-9. doi: 10.1291/hypres.31.921.
19 Telmisartan increases the permeability of endothelial cells through zonula occludens-1. Biol Pharm Bull. 2009 Mar;32(3):416-20. doi: 10.1248/bpb.32.416.
20 Differential regulation of tefluthrin and telmisartan on the gating charges of I(Na) activation and inactivation as well as on resurgent and persistent I(Na) in a pituitary cell line (GH(3)). Toxicol Lett. 2018 Mar 15;285:104-112. doi: 10.1016/j.toxlet.2018.01.002. Epub 2018 Jan 3.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
22 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
23 Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
24 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
25 Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
26 In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
27 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
28 Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.
29 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
30 Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
31 Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987 Dec;5(4):S139-42. doi: 10.1097/00004872-198712004-00023.
32 Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol. 2000 Jan;71(1):44-9. doi: 10.1902/jop.2000.71.1.44.
33 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
34 Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation. J Hypertens. 2008 Apr;26(4):737-46. doi: 10.1097/HJH.0b013e3282f4d1bd.
35 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
36 Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine. 2000 Oct;12(10):1566-9. doi: 10.1006/cyto.2000.0756.
37 A cell-based Rb(+)-flux assay of the Kv1.3 potassium channel. Assay Drug Dev Technol. 2007 Jun;5(3):373-80. doi: 10.1089/adt.2006.004.
38 Nifedipine inhibits vascular smooth muscle cell dedifferentiation via downregulation of Akt signaling. Hypertension. 2010 Aug;56(2):247-52. doi: 10.1161/HYPERTENSIONAHA.110.149781. Epub 2010 Jun 7.
39 Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J Cardiovasc Pharmacol. 2002 Jul;40(1):146-52. doi: 10.1097/00005344-200207000-00018.
40 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
41 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
42 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.